Compare AKR & RCUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AKR | RCUS |
|---|---|---|
| Founded | 1993 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.7B | 2.8B |
| IPO Year | 1993 | 2018 |
| Metric | AKR | RCUS |
|---|---|---|
| Price | $20.98 | $20.03 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 9 |
| Target Price | $22.00 | ★ $28.89 |
| AVG Volume (30 Days) | ★ 1.4M | 1.2M |
| Earning Date | 02-10-2026 | 02-24-2026 |
| Dividend Yield | ★ 3.81% | N/A |
| EPS Growth | ★ 18.54 | N/A |
| EPS | ★ 0.12 | N/A |
| Revenue | ★ $389,489,000.00 | $240,000,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $16.18 | N/A |
| P/E Ratio | $170.09 | ★ N/A |
| Revenue Growth | ★ 6.01 | N/A |
| 52 Week Low | $16.98 | $6.50 |
| 52 Week High | $24.95 | $26.40 |
| Indicator | AKR | RCUS |
|---|---|---|
| Relative Strength Index (RSI) | 62.83 | 42.95 |
| Support Level | $19.68 | $19.91 |
| Resistance Level | $19.86 | $22.29 |
| Average True Range (ATR) | 0.41 | 1.10 |
| MACD | 0.10 | -0.19 |
| Stochastic Oscillator | 100.00 | 18.35 |
Acadia Realty Trust is a real estate investment trust that specializes in the operation, management, leasing, renovation, and acquisition of shopping centers and mixed-use properties with retail components. The company operates through three segments: Core Portfolio segment consists primarily of high-quality retail properties located primarily in high-barrier-to-entry, densely-populated metropolitan areas with a long-term investment horizon; Investment Management segment holds primarily retail real estate in which the company co-invests with high-quality institutional investors; and Structured Financing segment consists of earnings and expenses related to notes and mortgages receivable Fees earned by the company as the general partner or managing member through Investment Management.
Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB598, Casdatifan among others. Arcus conducts clinical trials for different types of cancers such as Lung, Colorectal, Pancreatic, and others. The company operates through a single segment which is the business of developing and commercializing immunotherapies.